

Accepted Manuscript

Antipsychotic use and risk of hospitalisation or death due to pneumonia in persons with and without Alzheimer's disease

Anna-Maija Tolppanen, PhD, Marjaana Koponen, MSc (Pharm), Antti Tanskanen, Phil Lic, Piia Lavikainen, MSc, Reijo Sund, DSocSc, Jari Tiihonen, MD, PhD, Sirpa Hartikainen, MD, PhD, Heidi Taipale, PhD (Pharm)

PII: S0012-3692(16)50246-3

DOI: [10.1016/j.chest.2016.06.004](https://doi.org/10.1016/j.chest.2016.06.004)

Reference: CHEST 498

To appear in: *CHEST*


Received Date: 2 March 2016

Revised Date: 4 May 2016

Accepted Date: 1 June 2016

Please cite this article as: Tolppanen AM, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S, Taipale H, Antipsychotic use and risk of hospitalisation or death due to pneumonia in persons with and without Alzheimer's disease, *CHEST* (2016), doi: 10.1016/j.chest.2016.06.004.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 Word count 2861 (main text), 250 (abstract),

2 **Antipsychotic use and risk of hospitalisation or death due to pneumonia in**
3 **persons with and without Alzheimer's disease**

4 Short title: antipsychotic use and pneumonia risk

5 Anna-Maija Tolppanen, PhD;^{1,2} Marjaana Koponen, MSc (Pharm);^{1,3} Antti
6 Tanskanen, Phil Lic;^{5,6,7} Piia Lavikainen, MSc;^{1,3,8} Reijo Sund, DSocSc;⁹ Jari
7 Tiihonen, MD, PhD;^{5,6} Sirpa Hartikainen, MD, PhD;^{1,3,4}, Heidi Taipale, PhD
8 (Pharm);^{1,3,5,6}

9 ¹School of Pharmacy, University of Eastern Finland, Kuopio, Finland

10 ²Research Centre for Comparative Effectiveness and Patient Safety (RECEPS),
11 University of Eastern Finland, Kuopio, Finland

12 ³Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio,
13 Finland

14 ⁴Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland

15 ⁵Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland

16 ⁶Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

17 ⁷National Institute for Health and Welfare, Helsinki, Finland

18 ⁸Department of Pharmacology, Drug Development and Therapeutics, University of
19 Turku, Turku, Finland

20 ⁹Centre for Research Methods, Department of Social Research, University of
21 Helsinki, Helsinki, Finland

22
23 Correspondence to: Anna-Maija Tolppanen, School of Pharmacy, University of
24 Eastern Finland, PL 1627, 70211 Kuopio, Finland. email anna-maija.tolppanen@uef.fi

25 Summary of conflict of interest statements:

26 JT has served as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly,
27 AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees
28 for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline, lecture fees
29 from Janssen-Cilag, Bristol-Myers Squibb, Eli Lilly, Pfizer, Lundbeck,
30 GlaxoSmithKline, AstraZeneca and Novartis; and grant from Stanley Foundation. JT
31 is a member of advisory board in AstraZeneca, Janssen-Cilag, and Otsuka. MK has
32 received personal research grant from Oy H. Lundbeck Ab foundation outside the
33 submitted work. SH has received a lecturing fee from MSD. Other authors declare no
34 conflicts of interest.

35 Search terms: Alzheimer's disease, antipsychotics, pneumonia, observational studies,
36 register-based studies, cohort study, case-crossover, risperidone, quetiapine,
37 haloperidol

38 Funding information: None

39 No prior abstract publication/presentation

40

Download English Version:

<https://daneshyari.com/en/article/5952075>

Download Persian Version:

<https://daneshyari.com/article/5952075>

[Daneshyari.com](https://daneshyari.com)